GLOBAL NUCLEAR MEDICINE (MEDICAL ISOTOPES/RADIOISOTOPES/ RADIOPHARMACEUTICALS) MARKET IN PET/SPECT IMAGING & THERAPY Competitive Landscape,
Current Trends & Forecasts (2010 – 2015) MarketsandMarkets [email protected] www.marketsandmarkets.com
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
MarketsandMarkets is a global market research and consulting company based in the U.S. We
publish strategically analyzed market research reports and serve as a business intelligence
partner to Fortune 500 companies across the world. MarketsandMarkets also provides
multi-client reports, company profiles, databases, and custom research services.
MarketsandMarkets
covers
thirteen
industry
verticals,
including
advanced
materials,
automotives and transportation, banking and financial services, biotechnology, chemicals,
consumer, goods energy and power, food and beverages, industrial automation, medical
devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
Copyright © 2012 MarketsandMarkets
All Rights Reserved. This document contains highly confidential information and is the sole
property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise
reproduced without the approval of MarketsandMarkets.
MarketsandMarkets
2
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
TABLE OF CONTENTS EXECUTIVE SUMMARY .................................................................................................5

MARKET SCENARIO..................................................................... 5
1 SUMMARY..................................................................................................................7
2 MARKET OVERVIEW ..............................................................................................8
2.1
MARKET SEGMENTATION ............................................................ 8
3 RADIOPHARMACEUTICAL MARKET, BY ISOTOPES .................................. 10
3.1
LACK OF AVAILABILITY OF TECHNETIUM ................................. 10
4 RADIOPHARMACEUTICAL MARKET, BY ROUTES OF ADMINISTRATION (ROA) .................................................................................. 12
5 RADIOPHARMACEUTICAL MARKET, BY APPLICATIONS ........................ 13
6 GEOGRAPHIC ANALYSIS (CONSUMPTION) .................................................. 14
6.1
JAPAN....................................................................................... 14
MarketsandMarkets
3
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
LIST OF TABLES TABLE 1
RADIOPHARMACEUTICAL MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($MILLION)
7
TABLE 2
TECHNETIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($THOUSAND)
10
TABLE 3
NORTH AMERICA: THALLIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
11
TABLE 4
INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
12
TABLE 5
DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
13
TABLE 6
JAPAN: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
14
LIST OF FIGURES FIGURE 1
RADIOPHARMACEUTICAL MARKET, BY RADIOISOTOPES, 2008 – 2015
6
FIGURE 2
RADIOPHARMACEUTICALS: MARKET SEGMENTATION
8
MarketsandMarkets
4
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
EXECUTIVE SUMMARY Radiopharmaceuticals are medical formulations which contain radioisotopes and are safe for
humans in diagnosis and therapy. Radioisotopes contribute in several sectors of the economy
such as food processing, medicine, agriculture, and research. Radioisotopes in medicine are
used
either
in
liquid
form
(radiopharmaceuticals)
or
solid
form
(sealed
source).
Radiopharmaceuticals are defined as those pharmaceuticals which incorporate one or more
radioactive isotopes. These are majorly used for diagnostic purposes. Technetium for single
photon emission computed tomography (SPECT) and fludeoxyglucose (FDG) for positron
emission tomography (PET) are the common radiopharmaceuticals used for diagnosis of
various diseases.
This market research report categorizes the global market for radiopharmaceuticals by types,
indications, applications, and route of administration. This study is based on primary and
secondary research, and analyzes the markets based on end-users, patents filed, and new
developments. The report also studies and analyzes trends and opportunities affecting the
market growth.
 MARKET SCENARIO
Driven by the increasing incidence of cardiac and cancer diseases, early and accurate
diagnosis,
increasing
radiopharmaceutical
awareness
market
is
and
expanding
estimated
to
application
reach
around
segment,
$XX
billion
the
global
in
2010.
Radiopharmaceuticals are used for the diagnosis and treatment of various ailments such as
cancer, cardiac, renal, and respiratory diseases among others. PET machines enable
radiologists in early detection of cancer, cardiac, and Alzheimer’s disease among the patients.
This would increase the demand for PET machines among the healthcare centers and
providers. Similarly, SPECT scanners have been on the forefront to bring about significant
changes in the diagnostic imaging equipment landscape with opportunities in the market for
neuroendocrine
tumor
imaging.
For
diagnostic
applications
of
radiopharmaceuticals,
radioisotopes such as FDG for PET and technetium for SPECT are most commonly used.
MarketsandMarkets
5
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
The global market for radiopharmaceuticals is significantly consolidated with players such as
Covidien (Ireland), GE Healthcare (UK), ANSTO (Australia), IBA (Belgium), Cardinal Health
(U.S.), and others. It is observed that in the study period, IBA, Nordion, and Cardinal Health
lead the market with respect to competitive developments. On the other hand, GE Healthcare
leads in terms of patents filed in the period between 2005 and 2011. GE Healthcare has filed
XX% of the total patents filed between 2005 and 2011.
FIGURE 1
RADIOPHARMACEUTICAL MARKET, BY RADIOISOTOPES,
2008 – 2015
2008
2009
2010
2015
Source: MarketsandMarkets
Of all the radioisotopes technetium accounts for the largest share i.e. XX% in 2010. Globally in
XX% of imaging processes, technetium is used as it has the advantage of generating an image
with minimum risk to the patient. Rise in PET machine installations and increasing number of
PET procedures would drive the demand for FDG.
MarketsandMarkets
6
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
1
SUMMARY TABLE 1
RADIOPHARMACEUTICAL MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
Region
2008
2009
2010
2015
CAGR%
(2010-2015)
North America
XX
XX
XX
XX
XX
Europe
XX
XX
XX
XX
XX
APAC
XX
XX
XX
XX
XX
Japan
XX
XX
XX
XX
XX
ROW
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: Expert interviews, Annual report, MarketsandMarkets analysis
North America commanded the largest share; i.e. XX% of the overall radiopharmaceuticals
market in 2010; and is expected to reach $XX billion in 2015, at a CAGR of XX% for the same
period.
MarketsandMarkets
7
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
2
MARKET OVERVIEW 2.1
MARKET SEGMENTATION
Radiopharmaceuticals are used for the diagnosis and treatment of various diseases such as
cancer, cardiac, bone scan, and others. This report analyzes the radiopharmaceuticals market
by types of isotopes, route of administration, and applications. Technetium accounts for the
largest share; i.e. around XX% in the radiopharmaceuticals market, as it has a half-life of XX
hours; thereby making it ideal for transportation. Moreover, handling with minimum damage
to the patient, it can combine with XX different carrier molecules which are able to target many
different organs. This segment consists of isotopes such as FDG, technetium, gallium, sodium
iodide, rhenium, thallium, yttrium, erbium, and others. Majority of the radiopharmaceuticals
are used for diagnosis (around XX%) with SPECT commanding XX% and PET commanding
XX%.
FIGURE 2
RADIOPHARMACEUTICALS: MARKET SEGMENTATION
Radiopharmaceutical Market
By Isotopes
By Route of
Administration
By Application
Treatment
Diagnosis
SPECT
PET
Source: MarketsandMarkets
MarketsandMarkets
8
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
Radiopharmaceuticals used in SPECT are technetium, thallium, gallium, yttrium, erbium, and
others. Of all these radiopharmaceuticals, technetium accounts for the largest share; i.e.
around XX% share. In PET, FDG radiopharmaceutical is majorly used (around XX%).
Radiopharmaceuticals are used for the diagnosis of various indications such as cancer, cardiac
diseases, neuroimaging, bone scan, and others.
MarketsandMarkets
9
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
3
RADIOPHARMACEUTICAL MARKET, BY ISOTOPES 3.1
LACK OF AVAILABILITY OF TECHNETIUM
About XX% of Technetium is produced by XX reactors including Chalk River Reactor (Canada),
BR-XX Reactor (Belgium), Orisis Reactor (France), High flux reactor (The Netherlands), and
Safari Reactor (South Africa). These reactors have been in the business for a very long time
around XX years. There has been shut down of two of the plants, leading to shortage of
molybdenum; the raw material for technetium. This forces the medical fraternity as well as the
industry players to find alternatives for technetium in terms of radioisotope; such as thallium
for cardiac scan or imaging techniques that do not require technetium like X-Ray for
bone scan.
TABLE 2
TECHNETIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
Region
2008
2009
2010
CAGR%
2015
(2010-2015)
North America
XX
XX
XX
XX
XX
Europe
XX
XX
XX
XX
XX
APAC
XX
XX
XX
XX
XX
Japan
XX
XX
XX
XX
XX
ROW
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: Expert interviews, Annual report, MarketsandMarkets analysis
MarketsandMarkets
10
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
North America commanded the largest share – XX% – of the global technetium radioisotope
market estimated at $XX million in 2010; and is expected to reach $XX billion in 2015, at a
CAGR of XX% from 2010 to 2015.
TABLE 3
NORTH AMERICA: THALLIUM MARKET REVENUE,
BY COUNTRIES, 2008 – 2015 ($THOUSAND)
Country
2008
2009
2010
2015
CAGR%
(2010-2015)
U.S.
XX
XX
XX
XX
XX
Canada
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: Expert interviews, Annual report, MarketsandMarkets analysis
U.S. commanded the major share i.e. XX% of the North America thallium market estimated at
$XX million in 2010; and is expected to reach $XX million in 2015, at a CAGR of XX% from
2010 to 2015.
MarketsandMarkets
11
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
4
RADIOPHARMACEUTICAL MARKET, BY ROUTES OF ADMINISTRATION (ROA) TABLE 4
INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
Region
2008
2009
2010
2015
CAGR%
(2010-2015)
North America
XX
XX
XX
XX
XX
Europe
XX
XX
XX
XX
XX
APAC
XX
XX
XX
XX
XX
Japan
XX
XX
XX
XX
XX
ROW
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: Expert interviews, Annual report, MarketsandMarkets analysis
North America commanded the largest share i.e. XX% of the global inhalation route of
administration market estimated at $XX million in 2010; and is expected to reach $XX million
in 2015, at a CAGR of XX% from 2010 to 2015.
MarketsandMarkets
12
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
5
RADIOPHARMACEUTICAL MARKET, BY APPLICATIONS TABLE 5
DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
Region
2008
2009
2010
CAGR%
2015
(2010-2015)
North America
XX
XX
XX
XX
XX
Europe
XX
XX
XX
XX
XX
APAC
XX
XX
XX
XX
XX
Japan
XX
XX
XX
XX
XX
ROW
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: Expert interviews, Annual report, MarketsandMarkets analysis
North
America
commanded
the
largest
share
i.e.
XX%
of
the
global
diagnostic
radiopharmaceutical market estimated at $XX billion in 2010; and is expected to reach
$XX billion in 2015, at a CAGR of XX% from 2010 to 2015.
MarketsandMarkets
13
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
6
GEOGRAPHIC ANALYSIS (CONSUMPTION) 6.1
JAPAN
Japan accounts for XX% of the global market for radiopharmaceuticals. The demographic
factors of Japan are boosting the growth of the market. The country has strong local players
such as Fujifilm. It has to import most of the raw material from the other countries.
TABLE 6
JAPAN: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
Radioisotope
2008
2009
2010
2015
CAGR%
(2010-2015)
Fludeoxyglucose
XX
XX
XX
XX
XX
Technetium
XX
XX
XX
XX
XX
Gallium
XX
XX
XX
XX
XX
Sodium iodide
XX
XX
XX
XX
XX
Iobenguane
XX
XX
XX
XX
XX
Rhenium
XX
XX
XX
XX
XX
Samarium
XX
XX
XX
XX
XX
Thallium
XX
XX
XX
XX
XX
Yttrium
XX
XX
XX
XX
XX
Erbium
XX
XX
XX
XX
XX
Others
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: Expert interviews, Annual reports, U.S. Industry and trade commission, MarketsandMarkets analysis
MarketsandMarkets
14
Global Nuclear Medicine (Medical Isotopes/Radioisotopes/Radiopharmaceuticals) Market in PET/SPECT Imaging & Therapy – Competitive Landscape, Current Trends & Forecasts
Technetium radioisotope accounted for the largest share; i.e. XX% of the overall market for
radioisotopes in Japan in the year 2010. This segment is expected to reach $XX million by
2015, at a CAGR of XX% for the same period.
MarketsandMarkets
15